Skip to Content
Merck
  • Aberrant AZIN2 and polyamine metabolism precipitates tau neuropathology.

Aberrant AZIN2 and polyamine metabolism precipitates tau neuropathology.

The Journal of clinical investigation (2021-02-16)
Leslie A Sandusky-Beltran, Andrii Kovalenko, Devon S Placides, Kevin Ratnasamy, Chao Ma, Jerry B Hunt, Huimin Liang, John Ivan T Calahatian, Camilla Michalski, Margaret Fahnestock, Laura J Blair, April L Darling, Jeremy D Baker, Sarah N Fontaine, Chad A Dickey, Joshua J Gamsby, Kevin R Nash, Erin Abner, Maj-Linda B Selenica, Daniel C Lee
ABSTRACT

Tauopathies display a spectrum of phenotypes from cognitive to affective behavioral impairments; however, mechanisms promoting tau pathology and how tau elicits behavioral impairment remain unclear. We report a unique interaction between polyamine metabolism, behavioral impairment, and tau fate. Polyamines are ubiquitous aliphatic molecules that support neuronal function, axonal integrity, and cognitive processing. Transient increases in polyamine metabolism hallmark the cell's response to various insults, known as the polyamine stress response (PSR). Dysregulation of gene transcripts associated with polyamine metabolism in Alzheimer's disease (AD) brains were observed, and we found that ornithine decarboxylase antizyme inhibitor 2 (AZIN2) increased to the greatest extent. We showed that sustained AZIN2 overexpression elicited a maladaptive PSR in mice with underlying tauopathy (MAPT P301S; PS19). AZIN2 also increased acetylpolyamines, augmented tau deposition, and promoted cognitive and affective behavioral impairments. Higher-order polyamines displaced microtubule-associated tau to facilitate polymerization but also decreased tau seeding and oligomerization. Conversely, acetylpolyamines promoted tau seeding and oligomers. These data suggest that tauopathies launch an altered enzymatic signature that endorses a feed-forward cycle of disease progression. Taken together, the tau-induced PSR affects behavior and disease continuance, but may also position the polyamine pathway as a potential entry point for plausible targets and treatments of tauopathy, including AD.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
N1-Acetylspermine trihydrochloride, ≥97.0% (TLC)
Sigma-Aldrich
Aminoguanidine hydrochloride, ≥98%
Sigma-Aldrich
Phosphatase Inhibitor Cocktail 2, aqueous solution (dark coloration may develop upon storage, which does not affect the activity)
Sigma-Aldrich
Putrescine dihydrochloride, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Protease Inhibitor Cocktail, for use with mammalian cell and tissue extracts, DMSO solution
Sigma-Aldrich
Phosphatase Inhibitor Cocktail 3, DMSO solution
Sigma-Aldrich
Spermine, suitable for cell culture, BioReagent
Sigma-Aldrich
Phenylmethanesulfonyl fluoride solution, ~0.1 M in ethanol (T)
Roche
Anti-HA-Biotin, High Affinity (3F10), from rat IgG1
Sigma-Aldrich
N-(4-Aminobutyl)acetamide
Sigma-Aldrich
Anti-Tau Antibody, a.a. 210-241, clone Tau-5, ascites fluid, clone Tau-5, Chemicon®